

**Supplementary Table 2.** Subgroup analysis with dapagliflozin-treated participants stratified by the presence of severe hepatic steatosis and significant liver fibrosis at baseline ( $n=30$ )

Liver parameters at baseline	No.	Baseline	Week 24	Paired <i>t</i> -test
CAP $\leq 279$ dB/m				
CAP	12	237 $\pm$ 18.4	233 $\pm$ 43.0	0.755
LS <sup>a</sup>	12	4.1 (3.4–8.0)	4.8 (3.4–5.4)	0.677
CAP $> 279$ dB/m				
CAP	18	317 $\pm$ 32.1	290 $\pm$ 42.5	0.008
LS <sup>a</sup>	18	6.2 (5.6–9.4)	5.4 (4.8–6.9)	0.001
LS $< 5.8$ kPa				
CAP	15	264 $\pm$ 42.7	260 $\pm$ 59.0	0.742
LS <sup>a</sup>	15	4.4 (3.5–5.3)	4.6 (3.6–4.9)	0.915
LS $\geq 5.8$ kPa				
CAP	15	307 $\pm$ 45.1	275 $\pm$ 43.5	$< 0.001$
LS <sup>a</sup>	15	8.9 (6.3–10.4)	6.7 (5.4–8.0)	0.008

Values are presented as mean  $\pm$  standard deviation or median (interquartile range). Severe hepatic steatosis was defined as CAP  $> 279$  dB/m; Significant liver fibrosis was defined as LS  $\geq 5.8$  kPa.

CAP, controlled attenuation parameter; LS, liver stiffness.

<sup>a</sup>Log-transformed before analysis.